A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson, David

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. [electronic resource] - European journal of cancer (Oxford, England : 1990) 11 2016 - 1-10 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1879-0852

10.1016/j.ejca.2016.08.026 doi


Abdominal Pain--chemically induced
Administration, Oral
Adult
Aged
Allosteric Regulation
Anorexia--chemically induced
Bile Duct Neoplasms--drug therapy
Carcinoma, Non-Small-Cell Lung--drug therapy
Cholangiocarcinoma--drug therapy
Chromatography, High Pressure Liquid
Chromatography, Liquid
Colorectal Neoplasms--drug therapy
Diarrhea--chemically induced
Drug Eruptions--etiology
Esophageal Neoplasms--drug therapy
Fatigue--chemically induced
Female
Glycogen Synthase Kinase 3 beta--drug effects
Humans
Lung Neoplasms--drug therapy
MAP Kinase Kinase 1--antagonists & inhibitors
MAP Kinase Kinase 2--antagonists & inhibitors
Male
Maximum Tolerated Dose
Mesothelioma--drug therapy
Middle Aged
Mitogen-Activated Protein Kinase 1--drug effects
Mitogen-Activated Protein Kinase 3--drug effects
Nausea--chemically induced
Neoplasms--drug therapy
Pancreatic Neoplasms--drug therapy
Phosphoproteins--drug effects
Protein Kinase Inhibitors--adverse effects
Proto-Oncogene Proteins c-akt--drug effects
Ribosomal Protein S6 Kinases, 70-kDa--drug effects
Tandem Mass Spectrometry
Uterine Cervical Neoplasms--drug therapy